缬沙坦与贝那普利联用治疗移植肾慢性损伤的远期效果

目的 探讨血管紧张素受体拮抗剂缬沙坦与血管紧张素转化酶抑制剂贝那普利联合应用治疗肾移植患者移植肾慢性损伤的远期效果. 方法非糖尿病患者肾移植术后尿蛋白＞0.5g/d或SCr＞177 mmol/L(＞2 mg/d)32例,随机分2组:①治疗组23例.男9例,女14例.平均40岁.病理诊断慢性移植物肾病(CAN)13例、环孢素中毒3例、肾小球疾病7例.②对照组9例.男4例,女5例.平均35岁.CAN 6例、环孢素中毒1例、肾小球疾病2例.治疗组给予缬沙坦(80mg/d)与贝那普利(20 mg,2次/d)联合治疗3年,对照组未进行此项处理.比较2组患者治疗前后SCr、24 h尿蛋白变化及移植肾生存时间.结果 随访3年后,治疗组SCr为(252.2±117.9)mmol/L,对照组为(375.3±203.0)mmol/L,2组比较差异有统计学意义(P＜0.05).治疗组CAN患者SCr为(282.4±147.3)mmol/L,对照组为(528.7±107.8)mmol/L,2组比较差异有统计学意义(P＜0.01).治疗组24 h尿蛋白为(1.0±0.6)g,对照组为(1.3±0.7)g,组问差异无统计学意义(P＞0.05).移植肾存活时间治疗组76个月,对照组为71个月,组间差异无统计学意义(P＞0.05).结论 缬沙坦与贝那普利联合应用可保护移植肾功能,对蛋白尿及移植肾远期存活的影响有待进一步观察.

Functional protection and long-term survival of renal allograft by the combination of ACE inhibitor and angiotensin receptor blocker

Objective To evaluate the role of the combination of angiotensin receptor blocker (ARB)and angiotensin corwerting enzyme inhibitor(ACEI)in functional protection and long-term survival of renal allograft. Methods Thirty-two renal transplant recipients without diabetes mellitus,whose albuminuria concentration in 24-hours collection was more than 0.5 g/d or serum Cr concentration was higher than 177 mmol/L,were randomly divided into experimental group(n=23,male 9 and female 14 cases,mean age 40 years)and control group(n=9,male 5 and female 4 cases,mean age 35 years).Combination of ARB(Valsartan,80rag Qd)and ACEI(Benazapril,20 mg Bid)theraPy was given to each patient every day for 3 years in experimental group.The recipients in control group never received this administration.The serum Cr concentration,albuminuria in 24-hours collection and survival of renal allograft were compared between the 2 groups after 3 years. Results There was significant difference(P＜0.05) of serum Cr concentration between experimental group and control group(252.2±117.9 mmol/L VS 375.3±203.0 mmol/L),especially for chronic allograft nephropathy (CAN)patieats(282.4±147.3 mmol/L vs 528.7±107.8 mmol/L,P＜0.01).There was no difference (P＞0.05)in terms of the values of alburninuria(1.0±0.6 g/d vs 1.3±0.7 g/d)and survival of renal allograft(76 months VS 71 months)after 3 years between 2 groups.Comclusion The administration of ARB+ACEI could protect function of renal allograft with different pathological changes especially for CAN.